Apixaban Reduces Complications, Helps Older Adults Spend More Time At Home After Blood Clots

Older adults recovering from superior humor clots often look agelong periods of hospitalization aliases rehabilitation owed to a higher complaint of recurrence. But a caller study suggests that nan prime of humor thinner whitethorn power really good patients retrieve and really overmuch clip they tin walk astatine location erstwhile treated for venous thromboembolism. Venous thromboembolism includes heavy vein thrombosis, a clot typically forming successful nan legs, and pulmonary embolism, a clot that travels to nan lungs.

Venous thromboembolism is simply a awesome wellness interest among older adults. It is much communal successful older adulthood and is associated pinch superior complications and accrued mortality. Because nan consequence of recurrent clots remains precocious aft an first event, galore patients require semipermanent anticoagulant therapy to forestall recurrence.

The study, "Comparative Effectiveness of Oral Anticoagulants and Home Time After Venous Thromboembolism successful Frail and Non-Frail Older Adults," was published successful nan American Journal of Hematology. Researchers analyzed Medicare claims information from 2015 to 2019 for patients treated pinch 1 of 3 commonly prescribed oral anticoagulants - apixaban, rivaroxaban, aliases warfarin - aft an acute humor clot.

Researchers, led by a squad from the Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife, studied much than 18,000 Medicare beneficiaries and recovered that patients treated pinch nan anticoagulant apixaban (Eliquis) for vulnerable humor clots knowledgeable less awesome complications and spent much days astatine location alternatively than successful hospitals aliases nursing accommodation compared pinch those treated pinch warfarin (Coumadin aliases Jantoven). The findings were observed successful some frail and non-frail older adults, pinch nan clearest benefits seen among non-frail patients.

Compared pinch warfarin, apixaban was associated pinch a little mixed consequence of recurrent humor clots aliases decease wrong 1 year, arsenic good arsenic little rates of awesome bleeding. Patients taking apixaban besides knowledgeable less days of "home clip loss," a measurement that captures clip spent successful hospitals, emergency departments, skilled nursing facilities, aliases mislaid clip owed to decease wrong 365 days if continuously enrolled successful Medicare. In contrast, rivaroxaban showed nary clear advantage complete warfarin for preventing complications and was associated pinch a greater nonaccomplishment of clip astatine location than apixaban.

Importantly, nan study examined outcomes separately for frail and non-frail older adults, a organization often underrepresented successful objective trials. Frailty - a information marked by reduced beingness resilience and accrued vulnerability to unwellness - tin power some really medications are processed by nan assemblage and nan consequence of bleeding aliases different complications. By combining measures of frailty pinch some objective outcomes and patient-centered measures specified arsenic location time, nan researchers aimed to supply real-world grounds to thief guideline curen decisions for older adults pinch humor clots.

Older adults pinch humor clots often look analyzable curen decisions, peculiarly erstwhile frailty is involved. Our findings propose that apixaban whitethorn connection a favorable equilibrium of effectiveness, safety, and nan expertise for patients to stay astatine home, which is an result that matters greatly to older adults and their families."

 Chanmi Park, MD, MPH, study's lead writer and adjunct intelligence II astatine nan Marcus Institute

The researchers opportunity their findings adhd important grounds to thief clinicians and patients take among disposable anticoagulant therapies, peculiarly for older adults whose curen goals whitethorn see maintaining independency and minimizing clip spent successful hospitals aliases attraction facilities.

In summation to Park, researchers were Sandra Shi, MD, MPH, adjunct intelligence II, Marcus Institute; Xiecheng Chen, PhD, information intelligence I, Marcus Institute; Anna L. Parks, MD, adjunct professor, University of Utah, Division of Hematology; and Dae Hyun Kim, MD, MPH, ScD, subordinate head and elder scientist, Marcus Institute.